Along with healthcare stocks in general, biotechnology stocks are not hitting any near-term highs in terms of share price performance. Chalk it up …
In any industry, there are always deals that are too good to be true and unfortunately, they usually are. The best thing to …
2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is …
Most biotech stocks have been under pressure recently, but as we approach the end of the year, many analysts are quite bullish as …
At just $68 million in market capitalization, Agile Therapeutics (AGRX) is anything but what you’d call “Big Pharma” — but it’s getting bigger. …
On Monday, when the FDA came out against Sarepta Therapeutics’ (SRPT) Duchenne muscular dystrophy drug Vyondys 53, investors knew the shockwaves would immediately …
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, …
Wall Street loves growth stocks — and for good reason. In 2018, according to Bank of America, “growth” oriented mutual funds outperformed “value” …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Deciphera Pharmaceuticals …
Foamix Pharmaceuticals (FOMX) may be the best drug stock opportunity you’ve never heard of — and you should probably prepare yourself to hear …
